4 completed, 1 terminated. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Terminated 1 |
Follow CER-001: new trials by email Literature Review of CER-001 trials Research Report on CER-001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases CER-001, Placebo - Familial Hypoalphalipoproteinemia | Phase 3 | Terminated | Cerenis Therapeutics, SA | 30 | 2015-12-01 | 2025-07-22 |
| CER-001 Atherosclerosis Regression ACS Trial CER-001, Placebo - Acute Coronary Syndromes | Phase 2 | Completed | Cerenis Therapeutics, SA | 301 | 2015-08-01 | 2019-02-11 |
| Exploratory Study of Plaque Regression CER-001 - Heterozygous Familial Hypercholesterolemia | Phase 2 | Completed | Cerenis Therapeutics, SA | 10 | 2012-01-01 | 2014-03-03 |
| Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects CER-001 - Homozygous Familial Hypercholesterolemia | Phase 2 | Completed | Cerenis Therapeutics, SA | 23 | 2011-11-01 | 2015-08-18 |
| Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial Placebo, CER-001 - Acute Coronary Syndrome | Phase 2 | Completed | Cerenis Therapeutics, SA | 507 | 2011-03-01 | 2014-03-03 |
Acute Coronary Syndrome (2) · Hyperlipoproteinemia Type II (2) · Homozygous Familial Hypercholesterolemia (1) · Hypoalphalipoproteinemias (1)
Canada (4) · Netherlands (4) · United States (4) · France (2) · Italy (2) · Australia (1) · Belgium (1) · Hungary (1) · Israel (1) · United Kingdom (1)
Jean-Claude Tardif, MD (2) · Connie Keyserling, MS (1) · Erik SG Stroes, MD PhD (1) · John J. Kastelein, MD PhD (1) · Stephen Nicholls, MD PhD (1)